1. Pink Sheet
  4. >>South Korea

Comprehensive Compensation Urged For COVID-19 Vaccine Injuries In Korea

Rising Calls For Prompt Government Action

 
• By Jung Won Shin

Calls to more aggressively, comprehensively and quickly provide compensation for injuries thought to be linked to COVID-19 vaccinations have been made in South Korea, as possible adverse effect cases increase along with the national vaccination program.

COVID-19 Vaccine
Additional Purchase Pact With Pfizer Amid Shortage Concerns • Source: Alamy

South Korean health authorities should come up with a system that can more aggressively and comprehensively protect people thought to be suffering adverse effects from COVID-19 vaccinations, rather than maintaining an approach of compensating only those that have clear proven causality, the Korean Medical Association (KMA) has urged.

The current slow and difficult compensation process in the country has come into the spotlight after the husband of a nursing aide in her 40s, who was diagnosed with acute...

More from South Korea

Korean Pharma Industry Proposes Policies As Election Nears

 
• By Jung Won Shin

As South Korea gears up for a snap presidential election, its biopharma industry proposes key desired policies to candidates, most of whom have not laid out detailed plans of their own for the sector.

DIA Korea: Medical Turmoil, Global Factors Blunt Korea’s Trial Edge

 
• By Jung Won Shin

DIA Korea hears how multiple domestic and global factors are affecting the environment for clinical trials in South Korea, and what actions may be taken to address this.

US Tariff Impact On Korea Dissected As Country Gears For Presidential Election

 
• By Jung Won Shin

Analysts expect a limited impact on South Korean pharma from US tariffs, even if imposed at a later date. Meanwhile, the early June domestic presidential election is set to determine the direction of policies in the sector.

Korea To Revise ‘Innovative Company’ Criteria Amid Calls From Foreign Industry

 
• By Jung Won Shin

South Korea announces planned revisions to a government scheme to designate "innovative" biopharma companies amid allegations of "discrimination" against foreign firms.

More from Asia